```html

Finnish Disease Heritage – Finnish Congenital Nephrosis

Overview

Finnish congenital nephrosis (FCN) is a rare, inherited kidney disorder that belongs to the group of conditions known as the Finnish disease heritage. It is characterized by a severe, early‑onset proteinuria (excess protein loss in the urine) that leads to progressive kidney damage, often culminating in end‑stage renal disease (ESRD) before the age of 15.

• Who it affects: The disease is autosomal recessive, meaning a child must inherit two defective copies of the responsible gene—one from each parent. It occurs almost exclusively in people of Finnish ancestry, although isolated cases have been reported in other Northern European populations.
• Prevalence: Approximately 1 in 25,000 live births in Finland carries the disease, making it one of the most common monogenic renal disorders in that country. Worldwide, the prevalence is < 0.01 % of the general population.
• Genetics: Mutations in the NPHS1 gene (encoding nephrin) are the most common cause. Rarely, mutations in NPHS2 (podocin) or other podocyte‑related genes can produce a clinically indistinguishable phenotype.

Because the condition presents in the neonatal period or early infancy, early recognition and appropriate management are crucial for preserving kidney function and improving long‑term outcomes.

Symptoms

The clinical picture of FCN is dominated by signs of massive protein loss and its systemic effects. Symptoms may vary in severity, but the following list captures the most frequently reported findings:

Renal‑related symptoms

• Nephrotic‑range proteinuria: Urine protein excretion > 3.5 g/24 h (often > 10 g in infants).
• Hypoalbuminemia: Low serum albumin (< 2.5 g/dL) leading to edema.
• Edema: Swelling of the face, abdomen (ascites), and lower extremities; may be severe enough to cause respiratory compromise.
• Hyperlipidemia: Elevated cholesterol and triglycerides secondary to low oncotic pressure.
• Hematuria: Microscopic or gross blood in the urine (less common).
• Progressive renal insufficiency: Rising creatinine and declining glomerular filtration rate (GFR) typically within the first 2–3 years of life.

Extra‑renal manifestations

• Failure to thrive: Poor weight gain despite adequate caloric intake.
• Hypotension or hypertension: Fluid shifts can cause low blood pressure; chronic kidney disease may later induce hypertension.
• Infections: Loss of immunoglobulins in the urine predisposes to respiratory and urinary tract infections.
• Thromboembolic events: Hypercoagulable state due to loss of antithrombin III and other anticoagulant proteins; may present as deep‑vein thrombosis or pulmonary embolism.
• Growth retardation: Chronic disease and steroid exposure (if used) can impair linear growth.

Causes and Risk Factors

Genetic cause

FCN is caused by biallelic (both copies) pathogenic variants in genes that encode proteins essential for the structure and function of the glomerular filtration barrier:

• NPHS1 (nephrin): Most common; > 90 % of Finnish cases. The classic “Fin-major” and “Fin-minor” founder mutations account for the majority of Finnish families.
• NPHS2 (podocin): Rare in Finnish patients but described in other populations; leads to a similar phenotype.
• Other podocyte genes (e.g., PLCE1, WT1, LAMB2). These cause atypical forms and are extremely rare.

Inheritance pattern

Autosomal recessive inheritance means that:

• Both parents are typically asymptomatic carriers.
• Each subsequent pregnancy carries a 25 % chance of being affected, a 50 % chance of being a carrier, and a 25 % chance of being completely unaffected.

Population risk factors

• Finnish ancestry: The carrier frequency for the “Fin-major” mutation is about 1 in 50, making Finland the region with the highest burden.
• Consanguinity: While not required in Finland, consanguineous unions increase the likelihood of homozygosity for rare mutations.
• Family history: Having a sibling or close relative with FCN markedly raises risk.

Diagnosis

Early diagnosis hinges on clinical suspicion in infants presenting with severe proteinuria and edema, followed by targeted laboratory and genetic testing.

Initial laboratory evaluation

• Urinalysis: Dipstick ≥ 3+ protein; quantitative 24‑hour urine protein ≥ 3.5 g.
• Serum chemistry: Low albumin, elevated cholesterol/triglycerides, normal or mildly increased creatinine in the first weeks of life.
• Complete blood count: May reveal anemia or thrombocytopenia secondary to chronic disease.

Imaging studies

• Renal ultrasound: Typically shows normal‑sized kidneys with increased echogenicity; no structural anomalies.
• Kidney biopsy (rarely needed): Shows diffuse foot‑process effacement on electron microscopy, but genetic confirmation is preferred.

Genetic testing

1. Targeted mutation analysis: For Finnish patients, testing for the “Fin-major” (c.928G>A, p.Arg310Stop) and “Fin-minor” (c.1213_1214delCT, p.Leu405fs) mutations is the first step.
2. Next‑generation sequencing (NGS) panels: If targeted testing is negative, a renal‑ciliopathy or nephrotic‑syndrome panel can detect rare variants in NPHS2, PLCE1, etc.
3. Whole‑exome sequencing (WES): Considered for atypical cases or when a broader genetic picture is needed.

Diagnostic criteria (simplified)

A diagnosis of FCN is made when all three of the following are present:

1. Onset of nephrotic‑range proteinuria before 3 months of age.
2. Genetic confirmation of pathogenic biallelic NPHS1 (or other relevant) mutations.
3. Exclusion of secondary causes (infection, drugs, systemic disease).

Treatment Options

There is no cure for FCN, but a combination of medical therapy, surgical interventions, and supportive care can delay progression to ESRD and improve quality of life.

Pharmacologic therapy

• Albumin infusions: Intravenous human albumin (1 g/kg) may be required acutely to treat severe hypoalbuminemia and edema.
• Angiotensin‑converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs): Reduce intraglomerular pressure and proteinuria. Starting dose of enalapril 0.1 mg/kg/day, titrated to 0.5 mg/kg/day as tolerated.
• Statins: For hyperlipidemia; pravastatin 0.5 mg/kg/day is commonly used in children.
• Anticoagulation: Low‑molecular‑weight heparin or warfarin may be indicated for patients with documented thrombosis or persistent low antithrombin III levels.
• Immunosuppressants (e.g., steroids, calcineurin inhibitors): Generally ineffective for the genetic form and are avoided due to side‑effects.

Renal replacement therapy (RRT)

Because most patients progress to ESRD before school age, early planning for RRT is essential.

• Peritoneal dialysis (PD): Preferred in infants and young children; allows home‑based therapy and preserves residual renal function.
• Hemodialysis (HD): Used when PD is contraindicated or fails.
• Kidney transplantation: The definitive treatment. Living‑related donor transplantation from a non‑carrier sibling or parent yields the best outcomes. Post‑transplant survival rates exceed 90 % at 5 years (Cleveland Clinic, 2022).

Lifestyle and supportive measures

• Nutrition: Low‑salt, moderate‑protein diet (1.5 g/kg/day) with supplementation of albumin, vitamins (especially D), and minerals (calcium, phosphorus).
• Fluid management: Tailored to maintain euvolemia; diuretics (furosemide) may be required for edema.
• Vaccinations: Keep immunizations up‑to‑date, especially pneumococcal and influenza vaccines, to reduce infection risk.
• Growth monitoring: Endocrinology referral for growth hormone therapy if height falls < 2nd percentile despite optimal nutrition.

Living with Finnish disease heritage – Finnish congenital nephrosis

Families face a lifelong journey that involves medical care, psychosocial support, and day‑to‑day adaptations.

Practical daily‑management tips

1. Medication schedule: Use a pillbox or smartphone reminder to ensure ACE inhibitors, statins, and any anticoagulant are taken consistently.
2. Fluid tracking: Keep a simple log of urine output and any swelling; report rapid weight gain (> 0.5 kg in 24 h) to the nephrologist.
3. Nutrition plan: Work with a renal dietitian to create low‑salt, protein‑adjusted meals; incorporate high‑calorie smoothies if appetite is poor.
4. Infection vigilance: Promptly treat fevers, coughs, or urinary symptoms; keep a list of antibiotics the child has tolerated in the past.
5. School accommodation: Provide the school nurse with a care plan, including emergency albumin infusion instructions and medication administration.
6. Psychological support: Connect with Finnish disease heritage patient groups; counseling can help address anxiety, especially around dialysis or transplantation.

Family planning considerations

• Genetic counseling is strongly recommended for couples where both are carriers.
• Pre‑implantation genetic diagnosis (PGD) or prenatal testing (chorionic villus sampling, amniocentesis) can detect affected embryos.

Prevention

Because FCN is a genetic disorder, primary prevention (preventing the disease from occurring) is not possible without altering the genome. However, secondary prevention—reducing disease severity and delaying progression—is achievable.

• Carrier screening: Targeted testing for the Finnish founder mutations in couples of Finnish descent before conception.
• Early detection: Routine urine dipstick screening at newborn check‑ups in high‑risk families can identify proteinuria before clinical edema develops.
• Optimal blood pressure control: Maintaining BP < 95th percentile for age reduces stress on the glomeruli.
• Prompt treatment of infections: Early antibiotics lower the risk of sepsis‑related kidney injury.

Complications

If FCN is not adequately managed, several serious complications can arise:

• End‑stage renal disease (ESRD): Typically before age 15; necessitates dialysis or transplantation.
• Thromboembolic events: Deep‑vein thrombosis, pulmonary embolism, or renal vein thrombosis.
• Severe infections: Loss of immunoglobulins predisposes to bacterial sepsis.
• Hypovolemia & shock: Rapid fluid shifts from massive protein loss.
• Growth retardation & pubertal delay: Chronic disease and steroid exposure may impair growth.
• Cardiovascular disease: Long‑term hyperlipidemia and hypertension increase later‑life risk.

When to Seek Emergency Care

---

**References**

• Mayo Clinic. “Congenital Nephrotic Syndrome.” Updated 2023.
• National Institutes of Health (NIH). “NPHS1‑related disease.” Genetics Home Reference, 2022.
• Cleveland Clinic. “Kidney Transplant Outcomes in Pediatric Patients.” 2022.
• World Health Organization (WHO). “Guidelines for the Management of Protein‑uric Kidney Disease.” 2021.
• Centre for Genetic Medicine, University of Helsinki. “Finnish Disease Heritage – Current Knowledge.” 2022.

```